ArticleJournal of clinical laboratory analysis2009
Prevalence characterization of extended-spectrum beta-lactamases among Escherichia coli isolates collected in Zhengzhou.
Article in Journal of clinical laboratory analysis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- bla CTX-M-152, a Novel Variant of CTX-M-group-25, Identified in a Study Performed on the Prevalence of Multidrug Resistance among Natural Inhabitants of River Yamuna, India.Frontiers in microbiology · 2016Article
- Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China.Annals of clinical microbiology and antimicrobials · 2015Article
- Characterization of two new CTX-M-25-group extended-spectrum β-lactamase variants identified in Escherichia coli isolates from Israel.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the prevalence and the diversity of extended-spectrum beta-lactamases (ESBLs) among Escherichia coli isolates in Zhengzhou, China.
methodsClinical isolates were collected and investigated from the first affiliated hospital of Zhengzhou University and its associated health-care facilities in Zhengzhou, China, during the period from January 2006 to June 2008. Antibiograms were performed on Mueller-Hinton agar plates with the disc-diffusion method and MICs were determined by the agar-dilution method. Total DNA was extracted with a Qiagen mini kit and screened by PCR.
resultsOf 94 nonduplicate ESBL-positive isolates, TEM-type was encoded in 74 and 79% of the ESBL isolates. Fifty-six isolates were SHV type ESBLs. CTX-M-1, CTX-M-14, CTX-M-25, and CTX-M-38 types were encoded in 30, 54, 6, and 4, respectively. OXA-1-type beta-lactamases were encoded in six and OXA-20-type was encoded in two isolates.
conclusionsWe describe a complex ESBL epidemiology. The study revealed a high rate of ESBL-producing E. coli isolates. TEM and CTX-M enzymes dominated in ESBL-positive E. coli isolates in Zhengzhou, China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.